<DOC>
	<DOCNO>NCT01417286</DOCNO>
	<brief_summary>This phase II trial study well give accelerate radiation therapy ( RT ) surgery work treat patient breast cancer . RT use high energy x ray kill tumor cell . Giving RT surgery may kill remain tumor cell</brief_summary>
	<brief_title>Accelerated Radiation Therapy After Surgery Treating Patients With Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Freedom local failure freedom regional failure . SECONDARY OBJECTIVES : I . Acute toxicity late toxicity use previously publish toxicity scale . II . To identify co-variates responsible poor cosmetic outcome woman reconstruct chest wall treat accelerated , hypofractionated radiotherapy . III . To correlate toxicity , cosmesis , local control molecular marker . OUTLINE : Patients undergo hypofractionated accelerated RT 11 weekday ( 15 elapse day ) within 21-63 day last surgery last course chemotherapy . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 2-8 week , every 3-6 month 3 year , every 6-12 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<criteria>Invasive ductal , medullary , papillary , colloid ( mucinous ) , tubular histology ; invasive lobular carcinoma allow American Joint Committee Cancer ( AJCC ) Stage IIa IIIc ( pathologic stage T0N13 , T1N13 , T2N13 , T3N03 , T4N03 , M0 status ) histologically confirm invasive carcinoma breast treat mastectomy either sentinel node biopsy axillary dissection ; inflammatory carcinoma ( T4d ) allow Patients locally advance breast cancer clinical exam diagnostics ( &gt; 3 cm and/or clinically nodepositive ) mastectomy induction chemotherapy allow Multifocal/multicentric disease allow Negative ink histologic margin mastectomy ( invasive cell margin ) positive margin pectoralis fascia skin Tamoxifen , Arimidex hormonal therapy allow ; may begin time relative radiation discretion treat physician Chemotherapy allow , chemotherapy indicate chemotherapy deliver first , follow radiation therapy begin 2163 day last cycle chemotherapy radiation therapy deliver first chemotherapy deliver earlier 21 day post radiation therapy ; neoadjuvant chemotherapy allow ; radiation therapy deliver mastectomy adjuvant chemotherapy describe Chest wall reconstruction allow The patient must enrol treatment planning 1463 day date last surgery last cycle chemotherapy , radiation must start within 2163 day date last surgery last cycle chemotherapy Signed studyspecific inform consent form prior study entry Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient distant metastasis ( M1 ) Patients ductal lobular carcinoma insitu alone ( invasive component ) patient nonepithelial breast malignancy sarcoma lymphoma Patient T1N0 T2N0 disease Prior radiation therapy chest Patients collagen vascular disease , specifically systemic lupus erythematosus , scleroderma , dermatomyositis Patients coexist medical condition life expectancy &lt; 2 year Patients psychiatric ( possible exception incompetence define New Jersey [ NJ ] law ) addictive disorder would preclude obtain informed consent Other malignancy , except nonmelanomatous skin cancer , &lt; 5 year prior participation study ; diseasefree interval prior carcinoma must continuous Women pregnant lactating due potential exposure fetus RT unknown effect RT lactate female Women able conceive unwilling practice effective method birth control ; woman childbearing potential must negative urine serum pregnancy test within 7 day prior treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>